International Clinical Trial: Study of EL219 vs Standard of Care for Early Antifungal Therapy of Suspected Invasive Mould Infections

Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07215273) titled 'Study of EL219 vs Standard of Care for Early Antifungal Therapy of Suspected Invasive Mould Infections' on Sept. 24.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: Elion Therapeutics, Inc.

Condition: Suspected Invasive Mould Infection

Intervention: Drug: EL219

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: November 2025

Target Sample Size: 80

To know more, visit https://clinicaltrials.gov/st...